FDA warns about increased risk of cancer relapse with long-t
Health care professionals should not prescribe long-term azithromycin for prophylaxis of bronchiolitis obliterans syndrome (BOS) to patients who undergo donor stem cell transplants because of the increased potential for cancer relapse and death, the US Food and Drug Administration (FDA) has warned.

Researchers identified this increased risk of cancer relapse and death while conducting a clinical trial investigating the effectiveness of long-term azithromycin to prevent bronchiolitis obliterans syndrome in patients who undergo donor, or allogenic, stem cell transplants for cancers of the blood and lymph nodes.

The researchers concluded that the risks of long-term azithromycin exposure after donor stem cell transplantation may exceed the benefits. The trial could not determine why the rates of cancer relapse and death were higher with azithromycin.

Read more here: https://www.fda.gov/Drugs/DrugSafety/ucm614085.htm
Dr. v●●●d c●●●●a and 2 other likes this1 share
Like
Comment
Share